• Capricor Therapeutics (CAPR) Upgraded by Zacks Investment Research to Buy

    Zacks Investment Research upgraded shares of Capricor Therapeutics (NASDAQ:CAPR) from a hold rating to a buy rating in a research report report …

    Read More
  • 0 0